Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice

Waser, Peter G.; Müller, Ulrich; Kreuter, Jörg; Berger, S.; Munz, K.; Kaiser, E. T.; Pfluger, B.

doi:10.1016/0378-5173(87)90219-5

Cited by 52 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These clusters were ascribed to macrophages (J. Maas, autoradiography specialist, Hoechst AG). In an earlier work (Waser et al 16) a similar appearance of radioactivity in the form of dots was identified as an accumulation of nanoparticles in macrophages by the combination of macro-and microautoradiography. In the oral study (Fig.…”

Section: Resultsmentioning

confidence: 96%

Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*

Löbenberg

Kreuter²

1996

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Macrophages play an important role in the immunopathogenesis of AIDS. The objective of this study was to investigate the possibility of specific targeting of antivirals such as azidothymidine (AZT) to macrophages, using nanoparticles as a colloidal drug carrier. The body distribution of AZT bound to nanoparticles and as a control solution was studied in rats after intravenous and peroral administration. 14C-Labeled AZT was bound to nanoparticles in the presence of bis(2-ethylhexyl)sulfosuccinate sodium. The radioactivity was measured in different organs including those containing large numbers of macrophages. After intravenous injection, the concentrations of AZT were up to 18 times higher in organs belonging to the reticuloendothelial system (RES) when the drug was bound to nanoparticles than after injection of an aqueous AZT solution. Likewise, after oral administration the nanoparticle formulation delivered AZT more efficiently to the RES than the aqueous solution. In addition, the blood concentration was significantly higher after oral administration of nanoparticles. These results demonstrate that nanoparticles are a promising drug-targeting system for AZT to the RES organs. The increase in drug availability at the sites containing abundant macrophages may allow a reduction in dosage to avoid systemic toxicity.

show abstract

Section: Resultsmentioning

confidence: 96%

Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*

Löbenberg

Kreuter²

1996

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that liposomes mostly accumulate in the organs of the reticuloendothelial system, such as the liver, spleen, and lung within the rst 15-30 min aer the intravenous administration of the liposomal formulation. 108 In general, liposomes with a particle size >5 mm could be trapped passively by the vascular network of the lung to obtain a lung-targeting effect. 46,109 With these size considerations, Cheng et al 110 developed dipyridamole (DIP) liposomes with a mean diameter of 4.434 AE 0.252 mm in a particle size range of 1.103 AE 0.080 and determined the drug (pyrimidopyrimidine) concentration in the lung, heart, liver, spleen, and kidney of mice at different time intervals aer intravenous administration.…”

Section: Effect Of Size Of Drug Delivery Vehicles On Lung-targeted Inmentioning

confidence: 99%

Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery

et al. 2014

View full text Add to dashboard Cite

The design of a drug delivery system and the fabrication of efficient, successful, and targeted drug carriers are two separate issues that require slightly different design parameters. The geometry of the drug carrier such as its size and shape, chemical structure, surface chemistry, and surface charge are among the key parameters that need to be optimized to achieve the desired therapeutic behaviour.We review here the effects of the size of the drug delivery carrier on its biodistribution, target specificity, body clearance rate and, most importantly, the therapeutic action of the drug. Pulmonary and intravenous drug administration are the main focus, with special emphasis on cancer therapeutics and lung-targeted drug delivery. The significance of the effect of the dimensional variations and size of the drug delivery carriers on appropriate controlled and targeted drug delivery is explored with the aim of both prohibiting excessive therapeutic loss via different clearance routes and overcoming sideeffects and toxicity.

show abstract

“…One of the major benefits of LDS is the reduction of drug toxicity, mainly due to the specific distribution to the target organ, and the lack of an early peak in the release of free drug. 18 It has been shown that the use of LDS for cancer treatment improves lifespan and inhibits tumour growth via an increased distribution to necrotic tissue. 19 20 The pharmacokinetics improvement in tumour growth inhibition, is associated with the injection of large copolymers commonly used as surfactants in LDS, which exhibit longer retention times in the blood.…”

mentioning

confidence: 99%

A Note on Regulatory Concerns and Toxicity Assessment in Lipid-Based Delivery Systems (LDS)

Souto¹,

Martins-Lopes²,

Lopes³

et al. 2009

j biomed nanotechnol

View full text Add to dashboard Cite

Lipid-based Delivery Systems (LDS) has been the focus of potential strategies in drug delivery for several years. A great deal of work has been invested on how to exploit their biocompatible and biodegradable nature, in combination with their nanosize range in a profitable way in the field of nanomedicines. A number of drugs loaded in LDS have been already tested in vivo successfully. However, in vivo behaviour of nanosized materials differs from their bulk counterparts (and also change drug properties), mainly depending on the particular LDS physicochemical characteristics. These may have huge impact on the toxicity of the system, despite the physiological nature of the lipid materials. This note on the regulatory concerns and toxicity assessment in LDS suggests that current knowledge of public and scientific communities is lacking, requiring intensive research and policy measures to provide a deep understanding on toxicological risks.

show abstract

Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice

Cited by 52 publications

References 15 publications

Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*

Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*

Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery

A Note on Regulatory Concerns and Toxicity Assessment in Lipid-Based Delivery Systems (LDS)

Contact Info

Product

Resources

About